Dynamin-Activating Compounds for Podocyte Cytoskeleton Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutics capable of activating dynamin to improve podocyte health and reduce proteinuria in patients with kidney disorders, as dynamin plays a critical role in maintaining the actin cytoskeleton and ultrafiltration barrier function in podocytes, which is compromised in kidney diseases.
Innovation Solution
Development of compounds that activate dynamin, such as those represented by Formula I, which can be administered to treat kidney disorders and injured podocytes, enhancing dynamin activity to restore the actin cytoskeleton and improve filtration function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dynamin is activated to improve podocyte health and reduce proteinuria, then kidney function is improved, but no specific therapeutic compounds were available before this invention
Solution Approach 1:
The patent applies parameter changes by developing small molecule compounds that modify the biochemical parameters of dynamin activation. The compounds change the activation state of dynamin from inactive to active, thereby improving podocyte health and reducing proteinuria through pharmacological intervention
2Object-generated harmful factors
If dynamin is cleaved by cathepsin L during kidney disease, then actin cytoskeleton is reorganized leading to proteinuria, but this pathological process cannot be reversed without specific therapeutics
Solution Approach 1:
The patent converts the harmful effect of dynamin cleavage and actin cytoskeleton disruption into a beneficial therapeutic outcome. By administering dynamin-activating compounds, the pathological reorganization is reversed, and podocyte function is restored, thereby converting the harmful proteinuria pathway into a beneficial therapeutic response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dynamin-activating compounds demonstrate robust kidney exposure and efficacy in preclinical models, reducing proteinuria and improving kidney function, with potential therapeutic benefits in kidney disorders.
Implementation Method 1
In normal podocytes, dynamin influences actin organization in a GTP-dependent manner. When dynamin is oligomerized into higher-order structures, it can induce actin polymerization independent of any downstream effectors.
Data Source
AI summary
The present disclosure provides compounds of Formula I, a free base form thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising the same, and methods of treating medical disorders using the same.